Cure8 research brief
Nurse-led, protocolized care can make delivery of complex biologic and small-molecule IBD treatments safer and more consistent.
The review translates guideline recommendations into practical domains that affect monitoring, education, and how clinics respond to problems — issues that matter to patients on advanced therapies.
Specialist IBD nurses, gastroenterologists, clinic managers, patients on biologic or small-molecule therapies, and caregivers.
This narrative review summarizes nursing- and clinic-level practices for safe delivery of advanced IBD therapies (biologics and small molecules).
It organizes evidence into seven nursing care domains — pretreatment assessment, therapy preparation, IV infusion management, self‑administered therapy management, clinical and laboratory monitoring, critical event management, and core therapy knowledge — and highlights protocol-driven safety steps, patient education, remote monitoring, and escalation pathways.
The review draws on guideline documents (ECCO, BSG, ACG) and published literature to translate recommendations into operational, nurse-led clinical pathways meant to improve consistency and safety in routine practice. It also includes a brief complementary section on emerging therapies and special clinical contexts.
Practical implications described include structured pretreatment checks, standardized infusion and home‑therapy processes, monitoring schedules (laboratory and remote), and predefined escalation routes for adverse events or complications.
The article is framed as guidance to inform development and formal evaluation of nurse‑led pathways rather than reporting new trial results.
Who should read this Clinicians and specialist IBD nurses setting up or refining advanced-therapy services; patients receiving biologics or small-molecule drugs and their caregivers interested in care pathways; clinic managers and quality leads planning service delivery.
The source is a narrative review synthesizing guideline and published evidence (abstract supplied). It aims to inform pathway development and evaluation but does not present new trial results. Implementation should be adapted locally.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors declare that they have no conflicts of interest relevant to the content of this article. Ethical approval: Not applicable. This study is based on a narrative review of published literature and did not involve human participants or patient data. Consent to participate: Not applicable. Consent to publish: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The findings show earlier and more frequent use of imaging, endoscopic assessment, anti-TNF therapy, and seton placement for active perianal fistulizing Crohn’s disease over recent years — practices that may affect...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
